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Abstract Asymmetric dimethylarginine (ADMA) has
been found as correlated with endothelial dysfunction and
oxidativestress.TherearefewstudiesregardingADMAand
nitric oxide (NO) levels in patients with migraine and
alterations of ADMA and NO levels during migraine attack
arenotwell-known.Therefore,inpresentstudy,weaimedto
measureNOandADMAlevelsinpatientswithmigraineand
compare them with the control group to investigate the
correlation between migraine, oxidative stress and endo-
thelial dysfunction. The migraine group consisted of 59
patients, including 22 sufferingfrom migraine with aura and
37 suffering from migraine without aura. The control group
consisted of 31 healthy volunteers without headache. The
patients in migraine group were divided into subgroups
based on whether attack period was present or not and
whether it was migraine with or without aura. Plasma
ADMA levels were measured using an enzyme-linked
immunosorbent assay method. Migraine patients had higher
concentrations of NO (35.6 ± 7.7, 31.0 ± 6.2 lmol/L,
respectively, p = 0.005) and ADMA (0.409 ± 0.028,
0.381 ± 0.044 lmol/L, respectively, p = 0.001) levels
when compared with the healthy controls. During migraine
attack, NO and ADMA levels were found to be signiﬁcantly
higher in migraine group as compared to control group
(respectively, p = 0.015, p = 0.014). Similarly, NO and
ADMA levels in the patients with migraine in the interictal
period were found to be signiﬁcantly higher as compared to
controlgroup(p = 0.011,p = 0.003).Inconclusion, higher
ADMA and NO levels of patients with migraine supported
that oxidative stress and endothelial dysfunction may have a
role in migraine pathogenesis.
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Introduction
Migraine is a common, chronic and disabling neurovascular
disorder that characterized by severe headache attacks with
photophobia,nausea,vomiting,autonomicsymptoms,andin
some patients with aura involving neurological symptoms.
Although the pathogenesis of migraine is still unclear, dif-
ferent vascular, neurological, and neuroinﬂammatory
mechanisms have been suggested [1, 2]. Ithas been reported
that nitric oxide (NO) plays a role during trigeminovascular
inﬂammation occurring during migraine attacks [2]. Nitric
oxide, which is formed by the constitutive isoforms of NO
synthase, endothelial nitric oxide synthase (eNOS) and
neuronal nitric oxide synthase (nNOS), plays an important
roles in the regulation of cerebral blood ﬂow and cell via-
bility and in the protection of nerve cells or ﬁbers against
pathogenic factors associated with neurological disorders
[3]. Enhanced endothelial NO and superoxide anion release
may cause migraine through cerebralblood ﬂowchanges. In
some studies, oxidative stress due to increased NO has been
found especially during attacks in patients with migraine [4,
5]. It is emphasized that neurogenic inﬂammation, endo-
thelial dysfunction and oxidative stress have a role in
migraine pathogenesis [1–5].
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[5]. Asymmetric dimethylarginine (ADMA) is nitric oxide
synthase inhibitor and ADMA has close association with
endothelial dysfunction and oxidative stress [6]. There is
limited number of studies investigating ADMA levels in
patients with migraine [7, 8]. No difference has been found
in ADMA and NO levels between migraine patients during
interictal period and healthy controls in a previous study
[7]. However, ADMA levels had not been investigated in
patients with migraine attack. The association between
ADMA and NO in migraine attack is not well-known [7].
For these purposes, in present study, the relationships
between migraine, oxidative stress and endothelial dys-
function were investigated by comparing NO and ADMA
levels in migraine patients with headache attack and
interictal period.
Patients and methods
A total of 59 (40 women and 19 men) consecutive newly
diagnosed migraine patients who did not receive any pro-
phylactic migraine medication were included in this study.
The study group consisted of 22 patients, suffering from
migraine with aura and 37 migraine patients without aura
that followed-up in the outpatient clinic, Department of
Neurology, Dicle University Hospital. Migraine was
diagnosed based on the criteria of the International Head-
ache Classiﬁcation II [9]. The patients in migraine group
were divided into subgroups as migraine in the attack
period (with and without aura) (n = 24) and migraine in
the interictal period (with and without aura) (n = 35). Age
range of the patients was 18–57 years (mean ± standard
deviation: 33.3 ± 9.4 years). Patients who had hyperten-
sion (known hypertension treated with antihypertensive
drugs, two or more blood pressure recordings greater than
140/90 mm Hg), coronary artery disease (angiographically
proven coronary lesions[50% or documented myocardial
infarction, angina pectoris, previous percutaneous coronary
intervention or coronary artery bypass grafting), diabetes
mellitus (known diabetes treated with diet or drugs or both;
or either a fasting serum glucose of more than 126 mg/dl),
stroke and renal disease were excluded from the study. The
control group included 31 healthy participants without a
history of headache, vascular diseases, hypertension, dia-
betes mellitus, and renal and cardiac diseases. The control
group comprises 19 women and 12 men. Mean age of the
control group was 30.7 ± 8 years (range, 18–50 years).
Informed consent was obtained from all participants and
the study protocol was approved by the local ethics com-
mittee. Blood sampling was performed within 2–5 h from
the onset of migraine headache or headache-free period in
the patients with migraine patients. Similarly, blood
sampling was also performed in healthy individuals. Each
collected blood sample was immediately centrifuged at
4,000 rpm ?4C for 10 min and then transferred into an
eppendorf tube. Samples were transferred on ice and kept
at -80C deep freeze until the end of the study which was
completed in 3 months. The method for plasma nitrite and
nitrate levels was based on the Griess reaction [10]. As NO
measurement is very difﬁcult in biological specimens,
because it is readily oxidized to nitrite (NO
2-) and sub-
sequently to nitrate (NO
3-) which serves as index param-
eters of NO production. Griess method was used as the
principle of the NO assay after the protein was removed
from the samples by salt precipitation, and the NO
3- in the
sample was reduced to NO
2- by activated cadmium
granules, which was equal to the NO concentration of the
sample [10]. The plasma ADMA levels were determined
using the enzyme-linked immunosorbent assay (Immundi-
agnostik; Bensheim, Germany) method as previously
described [11].
Statistical analysis
All statistical analyses were performed using the Statistical
Package for the Social Sciences (SPSS), version 11.5, for
Windows (SPSS, Chicago, IL, USA). Data were expressed
as mean ± standard deviation. The normality of the dis-
tribution for all variables was assessed by the Kolmogo-
rov–Smirnov test. Student’s t test was used for normally
distributed variables and Mann–Whitney U test was used
for non-parametric variables. Relationships between vari-
ables were analyzed by Pearson or Spearman correlation
analysis according to distribution type of parameters.
A p\0.05 was considered to be statistically signiﬁcant.
Results
Some demographical and biochemical variables ofthe study
and control groups are shown in Table 1. No differences
were found in mean age, body mass index (BMI), blood
pressure and levels of fasting blood glucose, cholesterol,
triglyceride, LDL and HDL between two groups (p[0.05).
The NO and ADMA concentrations of the studysubjects are
shown in Table 2. Migraine patients had higher concentra-
tions of NO (35.6 ± 7.7 vs. 31.0 ± 6.2 lmol/L, respec-
tively, p = 0.005) and ADMA (0.409 ± 0.028, 0.381 ±
0.044 lmol/L, respectively, p = 0.001) when compared
with healthy controls. NO and ADMA concentrations of the
migraine subgroups are shown in Table 3. No statistically
signiﬁcant difference was found between NO (35.3 ± 6.4,
35.8 ± 8.5 lmol/L, respectively, p[0.05) and ADMA
(0.407 ± 0.025, 0.410 ± 0.031 lmol/L, respectively,
p[0.05) levels during attack and interictal period in
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123migraine group. No statistically signiﬁcant difference was
determined between ADMA (0.410 ± 0.033 vs.
0.406 ± 0.017 lmol/L, p[0.05) and NO (35.9 ± 8.4 vs.
35.0 ± 6.5 lmol/L, p[0.05) levels of the patients with
aura as compared to the patients without aura in migraine
group. No statistically signiﬁcant correlation was found
between age, gender, attack frequency, disease duration and
NO and ADMA levels in migraine group (for each parame-
ter, p[0.05).
Discussion
Our study showed that plasma concentrations of ADMA
and NO were elevated in migraine patients as compared to
control subjects. The migraine during the headache attacks
does not lead any signiﬁcant difference in ADMA and NO
levels as compared to the migraine during interictal period.
Nitric oxide, a labile molecule with a half life of only a
few seconds is synthesized generally in the endothelium. It
is rapidly oxidized by tissue oxygen to the stable end
products, nitrate and nitrite. Thereby, to best index of
overall NO production in the circulation, is the total con-
centrations of both nitrate and nitrite [5, 6]. NO is one of
the substances that takes a part in the pathophysiology of
migraine. NO is involved in the regulation of the cerebral
vessels tone. NO may function as a signaling molecule in
controlling neuronal activity and is important in controlling
sensory inputs during migraine attack and interacting with
reactive oxygen substances (ROS), which may induce
headache through changes of cerebral blood ﬂow [12]. The
most important effect of NO is the activation of the soluble
guanylate cyclase. This enzyme causes the synthesis of
cyclic guanosine monophosphate (cGMP) and NO-cGMP
pathway in smooth vascular muscles causes vascular dila-
tion and relaxation [13, 14]. It is suggested that NO could
be an important mediator in the initiation or the propaga-
tion of a neurogenic cranial vessel inﬂammatory response
that might eventually result in a migraine attack [14]. It has
been found that the pathways consisting of NO synthesis
are activated in the experimental headache models such as
nitroglycerin-induced headache [15]. The increase of NO
may be caused by interactions with free ROS. The primary
product of the interaction between NO and superoxide
anion is peroxynitrite. Peroxynitrite is an aggressive and
potent cellular oxidant [16]. So, increased NO with
migraine patients may be associated with oxidative stress.
In addition, occurrence of peroxynitrite following NO
increase affects endothelia function [17]. Marked NO
increase in migraine group in our study strengthened the
correlation between oxidative stress and endothelia dys-
function in pathophysiology of migraine. Likewise, Yılmaz
et al. [5] suggested that NO may serve as useful markers to
show the increased oxidative stress in migraine patients.
Tafﬁ et al. [18] found signiﬁcant increased peroxynitrite as
a potent oxidant in platelets of patients with migraine
without aura during headache-free periods. It has been
reported that the migraine headache and the changes in
Table 1 Demographical and
biochemical variables of the
study and control groups
N.S. statistically not signiﬁcant
(p[0.05), BMI body mass
index
Migraine patients (n = 59) Controls (n = 31) p values
Age (years) 33.1 ± 9.9 30.7 ± 8.1 N.S.
Sex (M/F) 19/40 12/19 N.S.
HDL-C (mg/dl) 48.4 ± 13.6 50.1 ± 8.8 N.S.
LDL-C (mg/dl) 102.1 ± 23.8 95.7 ± 34.1 N.S.
Cholesterol (mg/dl) 174.6 ± 32.4 176.8 ± 31.2 N.S.
Fasting glucose (mg/dl) 92.7 ± 6.1 91.2 ± 4.9 N.S.
Systolic blood pressure (mmHg) 108.3 ± 12.3 106.1 ± 10.8 N.S.
BMI (kg/m
2) 26.2 ± 2.6 27.1 ± 3.2 N.S.
Table 2 Comparison of nitric oxide (NO) and asymmetric dimeth-
ylarginine (ADMA) levels of control and migraine groups
Migraine patients
(n = 59)
Controls
(n = 31)
p values
NO (lmol/L) 35.6 ± 7.7 31.0 ± 6.2 0.005
ADMA (lmol/L) 0.409 ± 0.028 0.381 ± 0.044 0.001
Table 3 Comparison of nitric
oxide (NO) and asymmetric
dimethylarginine (ADMA)
levels of migraine subgroups
N.S. statistically not signiﬁcant
(p[0.05)
Migraine during attack (n = 25) Interictal period (n = 24) p
NO (lmol/L) 35.3 ± 6.4 35.8 ± 8.5 N.S.
ADMA (lmol/L) 0.407 ± 0.025 0.410 ± 0.031 N.S.
Migraine with aura (n = 22) Without aura (n = 37) P
NO (lmol/L) 35.0 ± 6.5 35.9 ± 8.4 N.S.
ADMA (lmol/L) 0.406 ± 0.017 0.410 ± 0.033 N.S.
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123cerebral blood ﬂow during migraine attacks may be related
to the production of NO [16, 19]. Also, Shimomura et al.
[20] found that high concentrations of platelet nitrate/nitrite
ratio during migraine attacks. But, Shukla et al. [21] found
no changes in polymorphonuclear leukocyte, platelet and
plasma nitrite levels in patients with migraine. Addition-
ally, it is suggested that intranasal hydroxocobalamin, a
NO scavenger, may have a prophylactic effect in migraine
[22]. Highly increased NO levels of our migraine patients
during attack and interictal period as compared to the
controls are in concordance with the results of the most
studies [16–20].
In recent studies, a relationship between migraine, stroke
and cardiovascular diseases have been reported [23, 24].
Endothelial dysfunction is induced by numerous cardiovas-
cular risk factors and represents an early event in the
development of atherosclerosis [25]. ADMA are elevated in
several disease states, including those characterized by
endothelial dysfunction such as stroke, cardiovascular dis-
eases, hypertension, pre-eclampsia, atherosclerosis, hyper-
cholesterolemia, diabetes mellitus, and chronic kidney
disease [25, 26]. It is suggested that endothelial dysfunction
has a role in the pathogenesis of correlation between
migraine and stroke [24]. Therefore, in our study, ADMA
level, a marker of endothelial dysfunction, was measured in
migrainecases.Tothe contraryoftwopreviouslyconducted
studies, ADMA levels were found to be signiﬁcantly higher
inmigraine casescompared tothe control groupinour study
[7, 8]. This ﬁnding supports the roles of oxidative stress and
endothelialdysfunctioninmigraine pathogenesis.Our study
is the ﬁrst study determining ADMA elevations in migraine.
Possible reasons for increase in levels of both NO and
ADMA in the patients with migraine in our study may be as
follows: (1) decrease in activity of dimethylarginine
dimethylaminohydrolase (DDAH) enzyme, metabolizing
ADMA and/or (2) excess amounts of ADMA could have
been produced to compensate the abnormally increased NO
in the body. It has been demonstrated that DDAH activity is
regulated by NO [8, 27]. This implies that under certain
conditions when NO generation increases, DDAH activity
may be diminished. This would lead to accumulation of
ADMA and inhibition of NO synthase [26]. Therefore, it is
conceivable that an increase in ADMA in migraine might
represent a compensatory mechanism to decrease NO pro-
duction and consequently, to counterbalance excessive
vasodilatation. It is suggested that endothelial injury,
impaired endothelial vasoreactivity and increased carotid
artery intima media thickness occur with migraine and these
are associated with vascular risk factors [28]. In some stud-
ies, particularly migraine with aura has been found to be
associatedwithendothelialdysfunction.Ithasbeenreported
that there is evidence of increased endothelial activation in
premenopausal women with migraine, particularly in those
with migraine with aura, [29]. In a previous study, an eNOS
(Glu298Asp) gene polymorphism decreasing eNOS activity
has been determined more frequently in migraine patients
with aura [30]. In our study, ADMA levels of migraine
patients both with and without aura were found to be mark-
edly higherthan those ofthe healthy controls. When ADMA
levels of migraine patients with and without aura were
compared, slightly higher but not signiﬁcantly different
ADMA levels were found in patients without aura. These
ﬁndings indicate the possible endothelial dysfunction in
migraine patients both with and without aura. Findings of
increased ADMA and NO in migraine may lead to new
therapeutic strategies including probable antioxidant use for
management of migraine In the future, development and
enhancements of existing drugs may be accompanied by
increased efforts to develop truly new migraine drugs based
on knowledge of the pathophysiology [31, 32].
In conclusion, increased ADMA and NO levels of
migraine patients support the roles of oxidative stress and
endothelial dysfunction in migraine pathogenesis. Further
clinicalandbiochemicalstudiesareneededtoinvestigatethe
associations between migraine, stroke and ADMA and to
introducenewtherapeuticmodalitiesformigrainetreatment.
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